https://www.selleckchem.com/products/epz-5676.html
The development of treatments for cognitive deficits associated with central nervous system disorders is currently a significant medical need. Despite the great need for such therapeutics, a significant challenge in the drug development process is the paucity of robust biomarkers to assess target modulation and guide clinicaldecisions. We developed a novel, translatable biomarker of neuronal glutamate metabolism, the C-glutamate+glutamine (Glx) H3H4 labeling ratio, in nonhuman primates using localized H-magnetic resonance spectroscopy
Like
Comment
Share
